Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seems like the fud is turning it up a notch. Then again…..how much lower can the shorts risk taking it. Gladly been adding as the funds allowed. 250 for the 401k last week.
Everyone’s an expert on the type of statistic the company used these days.
Guess what, we have the premier statistician on board and good luck trying to twist anything THAT guy puts out.
And here I was thinking he meant it as “short change”
We won’t even talk about what it means in Ireland.
Then again, I am NOT offended by people calling a certain pizza a Hawaiian Pizza.
Curious to know your opinion on what you expect for Anavex over the next 12 months.
Eventually it seems like the MOA will prove correct as trials conclude and data analyzed. Each trial further cementing Anavex as the next BP.
Long strong and riding all shares to the end of the rainbow. Success or failure.
So, in summary, would you say that is why BIIB barely moved when their second drug got approved?
Investors assumed even though their drug got approved, it wasn’t a REAL win for the disease, just for the co.
Come on steady. You mean to say Amyloid clearing IS and when BP shows clearance it’s worth Billions…..?
Right now, EVERYTHING is a shot in the dark, even after 30 years of trials targeting one idea.
As of today, the new generation of therapies currently in trials are the most promising.
What BP is doing with their Amyloid submissions reeks of desperation.
Guess even they see the writing on the wall
I’ll say the same thing about the sava open label data that was said when Anavex ran the same type trial.
Meaningless
Missling said that the results released so far was ALL patients from BOTH active arms
Wouldn’t call it a failure. Just not nearly as impressive as the combined arm of Blarcamesine.
How about this:
Can the FDA keep the momentum going for rare disease drug approvals?
While trofinetide, which is being developed by Acadia Pharmaceuticals and Neuren Pharmaceuticals, has a PDUFA date in March, a regulatory decision for Anavex Life Sciences’ blarcamesine hydrochloride is also expected by the year’s end.
https://www.pharmaceutical-technology.com/features/can-the-fda-keep-the-momentum-going-for-rare-disease-drug-approvals/
As we all wait for the next move Anavex will make, it’s all the more encouraging that S1R is finally getting some attention from researchers.
Time, in fact, did give you the answer. AD P2b/3 trial met ALL endpoints.
Now we just wait for mainstream to no longer ignore and report the never before seen results.
Anavex is on the edge of a medical breakthrough yet you still waiting for confirmation?
Don’t drink the doubt kool-aid that’s being spread on the board.
For the past several years, fundamental research on Sigma-1R (S1R) protein has unveiled its necessity for maintaining proper cellular homeostasis through modulation of calcium and lipid exchange between the endoplasmic reticulum (ER) and mitochondria, ER-stress response, and many other mechanisms. Most of these processes, such as ER-stress response and autophagy, have been associated with neuroprotective roles. In fact, improving these mechanisms using S1R agonists was beneficial in several brain disorders including neurodegenerative diseases. In this review, we will examine S1R subcellular localization and describe S1R-associated biological activity within these specific compartments, i.e., the Mitochondrion-Associated ER Membrane (MAM), ER–Lipid Droplet (ER–LD) interface, ER–Plasma Membreane (ER–PM) interface, and the Nuclear Envelope (NE). We also discussed how the dysregulation of these pathways contributes to neurodegenerative diseases, while highlighting the cellular mechanisms and key binding partners engaged in these processes.
https://www.mdpi.com/1422-0067/24/3/1971
Lol.Where did that one get pulled out of?
Wait, I know where.
With that logic let’s do the following:
If drink alcohol, then you can become dizzy
2 If you become dizzy and are elderly then you may fall
3 If you are elderly and fall then statistically you will be dead in a couple days in the floor or in the hospital.
/*These if then statements == pure logic*/
What a pretty silly logic.
DO BETTER
On top of that, there’s this presentation that will be given by Christopher Missling in of all places in Europe, Germany!!!
Nov 08 2023 @ 1720
Execution of a Clinical Trial Using Precision Medicine in Neurological Diseases
Relevance of biomarkers in clinical studies
What can we learn from oncology
Involving whole blood transcriptomics analysis (RNAseq)
https://informaconnect.com/clinical-trials-europe/speakers/christopher-missling/
I’m sure there were more deaths from ARIA-E using those injection therapies, than Blarcamesine and stumbling in the dark.
Are they though…investors?
Or do they themselves have a “hidden” agenda
Kids kids….
In the long term, Anavex looks to be building something that is worth your attention.
Just a matter of time.
Bring on the next gen of AD therapies
Oh I saw your post. Why use them for one AD therapy and not for the second, especially when it’s from the same CO. targeting the same thing.
Oh…right. They are rarely used that’s why.
Time will tell if healthcare will buy into this approved therapy.
Let’s revisit this in say 3 years?
Wait a second.
So for $26k/yr, bi-weekly infusions, MRI for how long….. is actually a step forward for AD therapy?
The weird question is:
“The FDA did not hold a public advisory meeting for lecanemab before approving it.”
Why does everyone seem to think new data will be presented?
Once again defeats the whole purpose of going to an INVESTOR conference if you release any data BEFORE.
Eisai did just activate the patient assistance hotline for the drug.
Would love to see a form signing requirement, much like waving your rights to sue for that very reason.
As beneficial as 6 cups of coffee minus the side effects!
Perhaps. The potential will be much better reflected in the stock price
If you just sit back and watch for a few more months.
FIXED
I don’t assume. Assuming ends up making one look a certain way.
Time will tell who was giving a best effort opinion and who was telling an invented truth.
Good luck to you the New Year’s Eve
One gives his best interpretation while the other omits to create a narrative.
There’s a difference between the two. It’s night and day.
Still Chet compared to the new generation of potential drugs that are in trials.
Hence the heist to get things approved ASAP
A response I could agree with.
Seems as though safety is a non issue for any of the trials.
So if that is so, what’s the chances that Anavex will be AA AND start a P4
A non U.S. BP will do.
Hell, I’d prefer a EU one for there, Aus for there, and Asian one for everywhere else.
Burn the US BP Companies to the ground!!
Especially those that peddle harmful treatment as a benefit to mankind
Bunch of greedy and corrupt S.O.B.s
Let’s chalk that up with a starting list:
Catalysts to drive value throughout 2023
I think “NEVER BEFORE SEEN” is perfectly fine.
Combining Alzheimer’s and stabilize in the same sentence……
Looks like they are mixing up trial attacks. Wasn’t it Rett they used that attack strategy….
Desperation calls for throwing the entire book at Anavex. Heck, surprised they aren’t using the “printing press” days.
He’d eradicate himself if he wanted to expose frauds.
AF and Missling are on two totally different career paths.
M on possibly the breakthrough of this century, AF moving on to that next “awful CEO”.
Nope. There is only 1 reason why the likes of AF attack small promising bios like AVXL or NWBO.
Why would he even waste his breath on these Companies if there was no ulterior motive
You vote your shares how you chose.
As for me, I’ll continue voting FOR.
GLTA
Not sure what you’re insinuating, but my investment, even at this lowly moment, is still a few 100 % green.
I’m no victim of the CEO.
More like a victim of a corrupt WS.
I’m sure OTHER Alzheimer’s tickers will soon hit triple figures AGAIN, trying to pry shares away from retail investors of Anavex.
One last hurrah one might call it.
But I thought knowledgeable people said it was subtraction that was done wrong…..
Some things are purposely omitted for obvious reasons.
What a ticking time bomb Anavex is!!
Soon the media will not have a choice BUT to report it.
Poor Fudsters can’t seriously recommend an injection therapy FAR MORE inferior to A-273 can they…..